Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Induction Carboplatin/Nab-Paclitaxel/Durvalumab in Locally-Advanced SCCHN
NCT03174275Phase 2Active, not recruiting
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Start
- Dec 2017
- Primary completion
- Feb 2022
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of durvalumab in squamous cell carcinoma of the head and neck (HNSCC) (3 arms), sponsored by UNC Lineberger Comprehensive Cancer Center. Primary endpoint: Pathologic Complete Response Rate. Started Dec 2017; status: active, not recruiting.
02
Drugs
durvalumab
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT03174275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03174275.